A Phase I clinical trial presents veledimex – a drug-inducible gene therapy approach – as a promising treatment technique for glioblastoma.
Browsing: clinical trial
Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
A drug belonging to a new generation of acute migraine headache treatments, termed rimegepant, has been demonstrated to eliminate pain and reduce bothersome symptoms.
A recent clinical trial has demonstrated that the drug, IONIS-HTTRx, is safe for use in people with Huntington’s disease.
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
At ECTRIMS, we had the pleasure of speaking with Marianna Cortese about her research in multiple sclerosis, including her interest in the microbiome.
In a Phase III clinical trial, a novel drug termed GV-971 has shown promise for improving cognition in people with mild-to-moderate Alzheimer’s disease.
The MS-STAT2 trial is underway, with researchers investigating simvastatin as a potential treatment option for individuals with secondary progressive multiple sclerosis.
Traumatic brain injury and circulating biomarkers: the CREACTIVE trial, an interview with Guido Bertolini
In this interview, we spoke with Guido Bertolini about the first results from the CREACTIVE trial on circulating biomarkers in traumatic brain injury.
A Phase II clinical trial of ibudilast has revealed that the drug decreases progression of brain atrophy in patients with progressive multiple sclerosis.